Case report and review of a novel chromosomal abnormality in AML patient

NewsGuard 100/100 Score

A new research paper was published in Genes & Cancer on June 28, 2023, entitled, "A novel t (5; 17) (q35; q21) associated with t (8; 21) (q22; q22) in a patient with acute myeloid leukemia: case report and review of literature."

The t (8; 21) (q22; q22) with the resulting RUNX1- RUNX1T1 rearrangement is one of the most common cytogenetic abnormalities in acute myeloid leukemia (AML). It is associated with a favorable prognosis. The t (5; 17) (q35; q21) is an uncommon translocation, fuses the gene for the nucleophosmin (NPM) to the retinoic acid receptor α(RARA) and was described essentially in acute promyelocytic leukemia (APL) variant.

In a new paper, researchers Kmira Zahra, Wided Cherif, Gereisha Ahmed, Haifa Regaieg, Ben Sayed Nesrine, Monia Zaier, Wided Mootamri, Yosra Ben Youssef, Nejia Brahem, Halima Sennana, and Abderrahim Khelif from Farhat Hached University Hospital-Sousse-Tunisia present the case of a 19-year-old male patient who developed an AML with t (8; 21) (q22; q22) associated to t (5; 17) (q35; 21).

Morphology and immunophenotype of the leukemic cells were compatible with AML. The patient received chemotherapy based on cytarabine and anthracycline without all-trans retinoic acid (ATRA) followed by allogenic stem cell transplantation in first remission. To the best of the researchers' knowledge, this is the first report of an association between a rare translocation t (5; 17) and t (8; 21) in AML.

"In this report, we will discuss the prognosis of this association as well as the treatment."

Journal reference:

Zahra, K., et al. (2023) A novel t (5; 17) (q35; q21) associated with t (8; 21) (q22; q22) in a patient with acute myeloid leukemia: case report and review of literature. Genes & Cancer.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study uncovers 17 genes driving clonal hematopoiesis and links to aging and disease